Effect modification of polypharmacy on incident frailty by chronic kidney disease in older adults

BMC Geriatrics

Table 3 Modification of the effect of polypharmacy on incident frailty by CKD

	No Polypharmacy				Polypharmacy			OR (95% CI) for polypharmacy within the strata of CKD*
	Total	Number of participants with incident frailty (%)	OR (95% CI)		Total	Number of participants with incident frailty (%)	OR (95% CI)	OR (95% CI) for polypharmacy within the strata of CKD*
no CKD	121	9 (7.4)	Reference		46	4 (8.7)	0.95 (0.27, 3.36)	0.95 (0.27, 3.36)
CKD	263	37 (14.1)	1.23 (0.54, 2.79)		198	52 (26.3)	2.74 (1.19, 6.33)	2.23 (1.32, 3.78)
Measure of effect modification on the multiplicative scale:				Ratio of ORs (95% CI): 2.34 (0.61, 9.01)
Measure of effect modification on the additive scale:				RERI (95% CI): 1.56 (0.01, 3.12)

CKD: Chronic kidney disease defined as an estimated glomerular filtration rate based on the BIS2 equation < 60 mL/min/1.73m² and/or albuminuria defined as an albumin-creatinine ratio ≥ 30 mg/g; Polypharmacy defined as taking ≥ 5 drugs of regular prescription drugs (regular prescription polypharmacy); RERI: Relative excess risk due to interaction; OR: Odds ratio; 95% CI: 95% Confidence interval
*column represents results from the stratified analyses by CKD with the reference categories being no polypharmacy in each stratum of CKD
All ORs are adjusted for age, gender, short version of the Comparative Analysis of Social Mobility in Industrial Nations classification of education, marital status, Body mass index, Charlson comorbidity index, and smoking

ISSN: 1471-2318